Latest News

Favorable 4-year Outcomes for Patients With Myeloma Treated With Elotuzumab

Favorable 4-year Outcomes for Patients With Myeloma Treated With Elotuzumab

Four-year follow-up data of the ELOQUENT-2 trial demonstrated that elotuzumab plus lenalidomide/dexamethasone has ongoing efficacy among patients with relapsed/refractory multiple myeloma.

Patients With Hepatocellular Carcinoma May Benefit From TACE Plus Axitinib

Patients With Hepatocellular Carcinoma May Benefit From TACE Plus Axitinib

The combination of axitinib and TACE is safe and potentially efficacious for patients with inoperable hepatocellular carcinoma.

Evofosfamide Not Recommended in First-line Sarcoma Treatment

Evofosfamide Not Recommended in First-line Sarcoma Treatment

Adding evofosfamide to doxorubicin is not recommended as a first-line treatment for patients with advanced soft-tissue sarcoma.

Midostaurin Plus Chemotherapy Prolongs Survival in AML With FTL3 Mutation

Midostaurin Plus Chemotherapy Prolongs Survival in AML With FTL3 Mutation

Adding midostaurin — a multi-targeted kinase inhibitor — to chemotherapy prolongs overall survival (OS) among patients with newly diagnosed AML and an FLT3 mutation.

MRI Imaging in Adjunct With Mammograms Improves Secondary Breast Cancer Detection

MRI Imaging in Adjunct With Mammograms Improves Secondary Breast Cancer Detection

Younger women who have undergone breast conservation therapy may benefit from an MRI in addition to annual mammogram screenings.

FDA Approves Subcutaneous Rituximab and Hyaluronidase Human for Blood Cancers

FDA Approves Subcutaneous Rituximab and Hyaluronidase Human for Blood Cancers

The FDA granted approval to rituximab and hyaluronidase human as a subcutaneous injection for the treatment of follicular lymphoma, chronic lymphocytic leukemia, and DLBCL.

FDA Approves Dabrafenib and Trametinib for BRAFV600E-mutant NSCLC

FDA Approves Dabrafenib and Trametinib for BRAFV600E-mutant NSCLC

The US Food and Drug Administration approved the combination of dabrafenib and trametinib for metastatic non-small cell lung cancer (NSCLC) with a BRAFV600E mutation.

First-line Nivolumab Fails To Prolong Survival in Stage IV NSCLC

First-line Nivolumab Fails To Prolong Survival in Stage IV NSCLC

Study results suggest that first-line treatment of advanced NSCLC with nivolumab does not prolong PFS or OS compared with chemotherapy, though nivolumab had a better safety profile.

Pembrolizumab Shows Activity Among Some Young Patients With Advanced Sarcoma

Pembrolizumab Shows Activity Among Some Young Patients With Advanced Sarcoma

PD-1 inhibition with pembrolizumab may be an effective treatment option for adolescent and young adult patients with some sarcoma subtypes.

Potential Clinical Benefit in Multigene Hereditary Testing for Patients With Sarcoma

Potential Clinical Benefit in Multigene Hereditary Testing for Patients With Sarcoma

There may be potential clinical benefits to performing hereditary cancer risk assessments and multi-gene panel testing in patients with sarcoma.

Early Taxane Switching May Improve PSA Response Rates in Prostate Cancer

Early Taxane Switching May Improve PSA Response Rates in Prostate Cancer

Early switching from docetaxel to cabazitaxel or vice versa may lead to improved prostate-specific antigen response rates.

Once-daily Radiotherapy Not Superior to Twice-daily in SCLC

Once-daily Radiotherapy Not Superior to Twice-daily in SCLC

Once-daily radiotherapy is not superior to twice-daily treatment for patients with small-cell lung cancer receiving concurrent chemoradiotherapy.

Phase 3 Vadastuximab Talirine Trials Halted Due to Deaths

Phase 3 Vadastuximab Talirine Trials Halted Due to Deaths

The data showed a higher rate of death, including fatal infections, in the vadastuximab talirine arm compared with the chemotherapy-only arm.

Intervention-guided Program Improves Weight Loss Among African American Breast Cancer Survivors

Intervention-guided Program Improves Weight Loss Among African American Breast Cancer Survivors

An intervention-guided program improved weight loss compared with a self-guided program among African American breast cancer survivors.

Potential Drug- and Herb-Drug Interactions Among Patients With Cancer

Potential Drug- and Herb-Drug Interactions Among Patients With Cancer

Drug-drug and herb-drug interactions are common among patients with cancer and can have important clinical ramifications.

FDA Expands Daratumumab Approval for Multiple Myeloma

FDA Expands Daratumumab Approval for Multiple Myeloma

The FDA approved daratumumab in combination with pomalidomide and dexamethasone for the third-line treatment of patients with multiple myeloma.

Talimogene Laherparepvec Plus Ipilimumab Promising for Advanced Melanoma

Talimogene Laherparepvec Plus Ipilimumab Promising for Advanced Melanoma

Talimogene laherparepvec plus ipilimumab improves the overall response rate over ipilimumab alone among patients with unresected, advanced melanoma.

PD-L2 Expression May Be Associated With Response to Pembrolizumab in HNSCC

PD-L2 Expression May Be Associated With Response to Pembrolizumab in HNSCC

PD-L2 is associated with progression-free survival among patients with head and neck squamous cell carcinoma treated with pembrolizumab.

Phase 2 Trial of GL-0817 With Cyclophosphamide for Squamous Cell Carcinoma of the Oral Cavity

Phase 2 Trial of GL-0817 With Cyclophosphamide for Squamous Cell Carcinoma of the Oral Cavity

Researchers are evaluating whether GL-0817 is safe and efficacious for preventing recurrence among patients with a head and neck cancer subtype.

Phase 2 Trial of Poly-ICLC Vaccination for Solid Tumors

Phase 2 Trial of Poly-ICLC Vaccination for Solid Tumors

Researchers are evaluating whether poly-ICLC vaccination is safe and efficacious for patients with melanoma, head and neck cancer, sarcoma, or a non-melanoma skin cancer.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters